Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.
Journal Information
Full Title: Ther Clin Risk Manag
Abbreviation: Ther Clin Risk Manag
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Care Sciences & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure The authors report no conflicts of interest in this work."
"There is no funding to report."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025